Last reviewed · How we verify
Aspirin + Acid folic
Aspirin + Acid folic is a Antiplatelet agent + vitamin supplement Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Cardiovascular disease prevention or secondary prevention in patients with elevated homocysteine or folate deficiency.
Aspirin inhibits platelet aggregation via COX inhibition while folic acid supports cellular methylation and DNA synthesis.
Aspirin inhibits platelet aggregation via COX inhibition while folic acid supports cellular methylation and DNA synthesis. Used for Cardiovascular disease prevention or secondary prevention in patients with elevated homocysteine or folate deficiency.
At a glance
| Generic name | Aspirin + Acid folic |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antiplatelet agent + vitamin supplement |
| Target | COX-1 (aspirin); folate metabolism pathway (folic acid) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aspirin irreversibly acetylates cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and platelet aggregation to provide antiplatelet effects. Folic acid (vitamin B9) acts as a methyl donor and cofactor in one-carbon metabolism, supporting DNA synthesis and repair. The combination likely targets cardiovascular disease prevention or thrombotic conditions where both antiplatelet activity and folate supplementation may be beneficial.
Approved indications
- Cardiovascular disease prevention or secondary prevention in patients with elevated homocysteine or folate deficiency
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
Key clinical trials
- Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss (PHASE3)
- Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia (PHASE2)
- Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus (PHASE3)
- Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm Birth (PHASE3)
- Hydroxychloroquine in Prevention of Preeclampsia (NA)
- Hydroxychloroquine and Unexplained Recurrent Miscarriage (NA)
- C677T Methylenetetrahydrofolate Reductase Mutation
- A Therapeutic Protocol in Previous Failed ART Patients With High Total NK Cells (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin + Acid folic CI brief — competitive landscape report
- Aspirin + Acid folic updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Aspirin + Acid folic
What is Aspirin + Acid folic?
How does Aspirin + Acid folic work?
What is Aspirin + Acid folic used for?
Who makes Aspirin + Acid folic?
What drug class is Aspirin + Acid folic in?
What development phase is Aspirin + Acid folic in?
What are the side effects of Aspirin + Acid folic?
What does Aspirin + Acid folic target?
Related
- Drug class: All Antiplatelet agent + vitamin supplement drugs
- Target: All drugs targeting COX-1 (aspirin); folate metabolism pathway (folic acid)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Cardiovascular disease prevention or secondary prevention in patients with elevated homocysteine or folate deficiency
- Compare: Aspirin + Acid folic vs similar drugs
- Pricing: Aspirin + Acid folic cost, discount & access